[1] Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al.
Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1171–72; 1179; 1185. doi:10.1016/j.ejca.2013.09.002.
[2] WHO, I.: GLOBOCAN 2012: Prostate Cancer - Estimated Incidence, Mortality and Prevalence Worldwide in 2012. n.d.
[3] Pötzsch O, Rößger F. Bevölkerung Deutschlands bis 2060 - 13. koordinierte Bevölkerungsvorausberechnung: Statistisches Bundesamt, 2015. 2015.
[4] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37.
doi:10.1016/j.eururo.2013.09.046.
[5] Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer:
2007 update. J Urol 2007;177:2106–31. doi:10.1016/j.juro.2007.03.003.
[6] Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Version 2.0 – 1.
Aktualisierung 2011. Berlin: 2011.
[7] Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al.
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
J Natl Compr Canc Netw 2010;8:240–62.
[8] Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, et al. Impact of Patient Age at Treatment on Outcome Following Radical Retropubic Prostatectomy for Prostate Cancer. J Urol 2006;175:952–7.
doi:10.1016/S0022-5347(05)00339-3.
[9] Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol 2007;178:1933-7-8. doi:10.1016/j.juro.2007.07.016.
[10] Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, et al. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. Urol Oncol 2007;25:291–7. doi:10.1016/j.urolonc.2006.08.001.
[11] Kunz I, Musch M, Roggenbuck U, Klevecka V, Kroepfl D. Tumour
characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy. BJU Int 2013;111:E24-9.
doi:10.1111/j.1464-410X.2012.11368.x.
[12] Xylinas E, Ploussard G, Paul A, Gillion N, Vordos D, Hoznek A, et al.
[Laparoscopic radical prostatectomy in the elderly (>75 years old):
oncological and functional results]. Prog Urol 2010;20:116–20.
doi:10.1016/j.purol.2009.08.037.
[13] Labanaris AP, Witt JH, Zugor V. Robotic-assisted radical prostatectomy in men
≥75 years of age. Surgical, oncological and functional outcomes. Anticancer Res 2012;32:2085–9.
[14] Sun M, Trinh Q-D, Bianchi M, Hansen J, Abdollah F, Tian Z, et al. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of
missing data. BJU Int 2014;113:36–42. doi:10.1111/j.1464-410X.2012.11693.x.
[15] Europe in figures - Eurostat yearbook - Statistics Explained. 2014. 2014.
http://ec.europa.eu/eurostat/statistics-explained/index.php/Europe_in_figures_-_Eurostat_yearbook.
[16] Statistical Abstract of the United States: 2012. Births, Deaths, Marriages, and Divorces. United States Census Bureau, Washington, D.C. (2012) section 2 2012.
[17] Mandel P, Graefen M, Michl U, Huland H, Tilki D. The effect of age on functional outcomes after radical prostatectomy. Urol Oncol Semin Orig Investig 2015;33:203.e11-203.e18. doi:10.1016/j.urolonc.2015.01.015.
[18] Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer? J Clin Oncol 2003;21:3318–27. doi:10.1200/JCO.2003.09.034.
[19] Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, et al.
Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. Eur Urol 2015;68:53–8. doi:10.1016/j.eururo.2014.12.026.
[20] Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients.
J Urol 1993;150:379–85.
[21] Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al.
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Lancet (London, England) 2014;384:2027–35. doi:10.1016/S0140-6736(14)60525-0.
[22] SEER Cancer Statistics Review, 1975-2012, National Cancer Institute.
Bethesda, MD: 2015.
[23] Huggins C, Hodges C V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.
[24] Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, et al.
Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 2016;27:175–82.
doi:10.1007/s10552-015-0695-0.
[25] Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2015;193:403–13. doi:10.1016/j.juro.2014.07.123.
[26] Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50:935–9. doi:10.1016/j.eururo.2006.06.034.
[27] Zeegers MPA, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003;97:1894–903. doi:10.1002/cncr.11262.
[28] Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789–94.
[29] Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The
worldwide epidemiology of prostate cancer: perspectives from autopsy studies.
Can J Urol 2008;15:3866–71.
[30] Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998;90:1637–47.
[31] Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159–63.
[32] Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem
1989;264:1894–900.
[33] Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909–16. doi:10.1056/NEJM198710083171501.
[34] Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA
1995;273:289–94.
[35] Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.
[36] Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005;174:872–6; discussion 876.
doi:10.1097/01.ju.0000169262.18000.8a.
[37] Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283–90.
[38] Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283–91.
[39] Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407–13.
[40] Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, et al.
Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992;147:810–4.
[41] Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on
prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22:31–
7.
[42] Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al.
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind,
placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998;52:195-201-2.
[43] Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al.
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210–9. doi:10.1002/cncr.25568.
[44] Schröder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The
European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999;35:539–
43.
[45] Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico A V, Volk RJ, et al.
American Cancer Society guideline for the early detection of prostate cancer:
update 2010. CA Cancer J Clin 2010;60:70–98. doi:10.3322/caac.20066.
[46] Carter HB. Prostate cancers in men with low PSA levels--must we find them? N Engl J Med 2004;350:2292–4. doi:10.1056/NEJMe048003.
[47] Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW.
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology
1996;48:55–61.
[48] Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al.
Use of the percentage of free prostate-specific antigen to enhance
differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542–7.
[49] Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC.
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5–12.
[50] Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al.
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215–20.
[51] Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al.
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521–7.
doi:10.1093/jnci/djj410.
[52] Sölétormos G, Semjonow A, Sibley PEC, Lamerz R, Petersen PH, Albrecht W, et al. Biological variation of total prostate-specific antigen: a survey of
published estimates and consequences for clinical practice. Clin Chem 2005;51:1342–51. doi:10.1373/clinchem.2004.046086.
[53] Kundu SD, Roehl KA, Yu X, Antenor JA V, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer
aggressiveness. J Urol 2007;177:505–9. doi:10.1016/j.juro.2006.09.039.
[54] Loeb S, Sutherland DE, D’Amico A V, Roehl KA, Catalona WJ. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008;72:1116–20; discussion 1120.
doi:10.1016/j.urology.2008.01.082.
[55] Isharwal S, Makarov D V, Sokoll LJ, Landis P, Marlow C, Epstein JI, et al.
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011;77:763.e1-6.
doi:10.1016/j.urology.2010.07.526.
[56] McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread.
Am J Surg Pathol 1988;12:897–906.
[57] Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical
significance of multifocal prostate cancers in radical prostatectomy specimens.
Urology 2002;60:264–9.
[58] Sobin L, Gospodarowicz M, Wittekind C. TNM-Klassifikation maligner Tumore.
7. Auflage, Hoboken: Wiley-Blackwell: 2009.
[59] Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–32. doi:10.1093/jnci/djr500.
[60] Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
[61] Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107:882–91.
doi:10.1111/j.1464-410X.2010.10032.x.
[62] Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006;175:1605–12.
doi:10.1016/S0022-5347(05)00957-2.
[63] Lee HY, Lee HJ, Byun S-S, Lee SE, Hong SK, Kim SH. Classification of focal prostatic lesions on transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate cancer. Korean J Radiol 10:244–51.
doi:10.3348/kjr.2009.10.3.244.
[64] Tamsel S, Killi R, Hekimgil M, Altay B, Soydan S, Demirpolat G. Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels. J Med Imaging Radiat Oncol 2008;52:24–8.
doi:10.1111/j.1440-1673.2007.01906.x.
[65] Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–8.
[66] Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228–42.
[67] Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995;153:987–92.
[68] Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol 2016;69:428–35.
doi:10.1016/j.eururo.2015.06.046.
[69] Makarov D V, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095–101.
doi:10.1016/j.urology.2007.03.042.
[70] Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003;1:221–
6.
[71] Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD.
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843–8.
[72] Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995–1000.
doi:10.1043/0003-9985(2000)124<0995:PFIPC>2.0.CO;2.
[73] Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286–92.
[74] Svanholm H, Mygind H. Prostatic carcinoma reproducibility of histologic grading. Acta Pathol Microbiol Immunol Scand A 1985;93:67–71.
[75] Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Current practice of Gleason grading of prostate carcinoma. Virchows Arch
2006;448:111–8. doi:10.1007/s00428-005-0102-4.
[76] Roehl KA, Han M, Ramos CG, Antenor JA V, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910–4. doi:10.1097/01.ju.0000134888.22332.bb.
[77] D’Amico A V, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
JAMA 1998;280:969–74.
[78] Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730–3.
doi:10.1111/j.1464-410X.2008.08205.x.
[79] Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer:
99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287–97.
[80] Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171:2122–7.
[81] Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, et al.
Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009;55:801–14. doi:10.1016/j.eururo.2009.01.027.
[82] Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, et al. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int 2015;115:381–8.
doi:10.1111/bju.12639.
[83] Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22–9. doi:10.1016/j.eururo.2014.03.002.
[84] Hoeks CMA, Schouten MG, Bomers JGR, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62:902–9.
doi:10.1016/j.eururo.2012.01.047.
[85] Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751–6.
doi:10.1111/j.1464-410X.2005.05394.x.
[86] Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al.
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42. doi:10.1056/NEJMoa1311593.
[87] Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165–9. doi:10.1200/JCO.2005.03.3134.
[88] Young HH. VIII. Conservative Perineal Prostatectomy: The Results of Two Years’ Experience and Report of Seventy-Five Cases. Ann Surg 1905;41:549–
57.
[89] MEMMELAAR J. Total prostatovesiculectomy; retropubic approach. J Urol 1949;62:340–8.
[90] Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492–7.
[91] Budäus L, Isbarn H, Schlomm T, Heinzer H, Haese A, Steuber T, et al. Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 2009;56:317–24. doi:10.1016/j.eururo.2009.05.044.
[92] Rozet F, Galiano M, Cathelineau X, Barret E, Cathala N, Vallancien G.
Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J Urol 2005;174:908–11. doi:10.1097/01.ju.0000169260.42845.c9.
[93] Parsons JK, Bennett JL. Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy. Urology 2008;72:412–6.
doi:10.1016/j.urology.2007.11.026.
[94] Coelho RF, Rocco B, Patel MB, Orvieto MA, Chauhan S, Ficarra V, et al.
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol
2010;24:2003–15. doi:10.1089/end.2010.0295.
[95] Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, et al.
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037–63. doi:10.1016/j.eururo.2009.01.036.
[96] Briganti A, Chun FK-H, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al.
Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98:788–93. doi:10.1111/j.1464-410X.2006.06318.x.
[97] Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al.
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451–9. doi:10.1016/S1470-2045(11)70063-8.
[98] Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al.
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–50.
doi:10.1016/S1470-2045(05)70348-X.
[99] Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (London, England) 2002;360:103–6.
[100] Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–73. doi:10.1016/S1470-2045(10)70223-0.
[101] Lawton CA, Winter K, Grignon D, Pilepich M V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23:800–7. doi:10.1200/JCO.2005.08.141.
[102] Pilepich M V, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al.
Androgen suppression adjuvant to definitive radiotherapy in prostate
carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–90. doi:10.1016/j.ijrobp.2004.08.047.
[103] D’Amico A V, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–95. doi:10.1001/jama.299.3.289.
[104] Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497–504.
doi:10.1200/JCO.2007.14.9021.
[105] Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma?
Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366–73.
doi:10.1200/JCO.2006.10.5171.
[106] Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646–55. doi:10.1016/j.ijrobp.2007.04.003.
[107] Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 2011;80:6–16.
doi:10.1016/j.ijrobp.2010.11.074.
[108] Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically
localized prostate cancer. Ann Intern Med 2008;148:435–48.
[109] Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–
67. doi:10.1093/jnci/djh259.
[110] Goldner G, Bombosch V, Geinitz H, Becker G, Wachter S, Glocker S, et al.
Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol 2009;185:94–100.
doi:10.1007/s00066-009-1970-3.
[111] Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study.
Gastroenterology 2005;128:819–24.
[112] Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398–406.
[113] Ojha RP, Fischbach LA, Zhou Y, Felini MJ, Singh KP, Thertulien R. Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma. Cancer Epidemiol 2010;34:274–8.
doi:10.1016/j.canep.2010.04.003.
[114] Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al.
Radical prostatectomy, external beam radiotherapy or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25–33.
[115] Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57:263–7.
[116] D’amico A V, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, et al.
Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003;62:1063–7.
[117] Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Brachytherapy 2005;4:34–44. doi:10.1016/j.brachy.2004.12.001.
[118] Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, et al.
Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125
implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517–22.
[119] Koukourakis G, Kelekis N, Armonis V, Kouloulias V. Brachytherapy for prostate cancer: a systematic review. Adv Urol 2009:327945. doi:10.1155/2009/327945.
[120] Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, et al. Lack of benefit from a short course of androgen deprivation for
unfavorable prostate cancer patients treated with an accelerated
hypofractionated regime. Int J Radiat Oncol Biol Phys 2005;62:1322–31.
doi:10.1016/j.ijrobp.2004.12.053.
[121] Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, et al. Long-term outcome by risk factors using conformal high-dose-rate
brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:1048–55. doi:10.1016/j.ijrobp.2003.08.003.
[122] Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005;47:441–8. doi:10.1016/j.eururo.2004.11.014.
[123] Galalae RM, Kovács G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:81–90.